Trial NCT04326790
Publication Deftereos SG, JAMA, 2020
Primary outcome on the report: The coprimary end points of the biochemical phase were the difference in maximal high-sensitivity cardiac troponin (hs cTn) levels between the 2 groups and the time for C-reactive protein to reach levels greater than 3 times the upper reference limit. The primary end point of the clinical phase was the time from baseline to clinical deterioration, defined as a 2-grade increase on an ordinal clinical scale, based on the World Health Organization R&D Blueprint Ordinal Clinical Scale, as used in previously published studies, within a time frame of 3 weeks after randomization or until hospital discharge (whichever occurred first)